What does OnKure Therapeutics, Inc. do?
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka)…
What is OnKure Therapeutics, Inc.'s P/E and P/B ratio?
OnKure Therapeutics, Inc. has a P/E ratio of -0.8 and a P/B ratio of 0.61.
What is OnKure Therapeutics, Inc.'s debt-to-equity ratio?
OnKure Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does OnKure Therapeutics, Inc. owe compared with what it owns?
OnKure Therapeutics, Inc. owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.
What is OnKure Therapeutics, Inc.'s Positivity rank?
OnKure Therapeutics, Inc. is ranked #2,307 of 6,775 companies globally and #671 of 4,000 in United States on PositoAI, with a Positivity Score of 21,699.
Does OnKure Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for OnKure Therapeutics, Inc..
Where can I read the latest news about OnKure Therapeutics, Inc.?
Recent headlines about OnKure Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does OnKure Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of OnKure Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.